Back to News
Market Impact: 0.3
BioCryst Reports Third Quarter 2026 Financial Results
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
BioCryst Pharmaceuticals reported third-quarter 2026 total net revenue of $180.3 million, including $174.8 million from ORLADEYO. The company recorded operating profit of $53.3 million and net income of $37.9 million; the provided article text includes no year-over-year comparisons or consensus figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
BCRX0.75
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Qualcomm issues disappointing earnings forecast as memory shortage weighs on smartphone sales
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- Nifty Bounces Back to Beat All of Asia on Foreign Flows, Earnings
- Snap shares fall over 10% on third-quarter earnings miss